Boundless Bio News Today

Boundless Bio, Inc. (BOLD.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Boundless Bio, Inc. | Nasdaq: BOLD | Nasdaq

USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people ...

Here are Monday's biggest calls on Wall Street.

STARMAP is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide...

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled...

A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.

(Bloomberg) -- Shares of Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, fell 9% after raising $100 million in a US initial public offering.Most Read from BloombergBankman-Fried Is Sentenced to 25 Years in Prison Over FTX CollapseTesla’s $25,000 Car Means Tossing Out the 100-Year-Old Assembly LineDubai Is Losing Its Allure for Wealthy RussiansLondon Insurers Face Baltimore Bridge Payouts Worth BillionsUBS Banker’s Frustration Expose...

Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.

James Christensen, Ph.D., and Nancy Whiting, Pharm.D., join Board of DirectorsGeorge Demetri, M.D., to serve as first member of Clinical Advisory BoardSAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver...

Several major companies have announced CFO transitions or departures, but still need to find a permanent successor.